WE ARE APIS, a next-generation molecular diagnostics business, committed to realising the potential of systems biology and medicine in the diagnosis and personalisation of treatment. We seek to develop biomarkers that deliver significant improvements in the prediction and prevention of disease
We are developing tests to target key areas with unmet clinical need, including:
- Infectious diseases
- Reproductive diagnostics
We also have plans to expand into liver and lung disease, pharmacogenomics and non-invasive reproductive diagnostics.
Our business model rests on three pillars – a biomarker industrial research program, the fast-tracking of biomarkers and diagnostic platforms for market sale and contract development. Backed by a combination of private and public funding, our headcount has rapidly increased since our inception in January this year. Further growth is supported by our business plan, and we predict significant growth in the size of the business in the next 3 years.
Operating from the heart of Manchester’s world-renowned Genomic Campus, we have unique opportunities to collaborate closely with the hospitals and universities to positively influence the future of medicine and healthcare both locally and internationally.
For such a young company, we already benefit from over 100 years combined experience in the diagnostics industry, we are now looking to build on this expertise via the attraction of talented individuals in a Senior Scientist capacity.